| human | Q5 |
| P213 | ISNI | 0000000351896217 |
| P244 | Library of Congress authority ID | no2015081178 |
| P496 | ORCID iD | 0000-0001-8902-2473 |
| P3829 | Publons author ID | 2890626 |
| P1053 | ResearcherID | B-1319-2008 |
| P1153 | Scopus author ID | 7006560946 |
| P214 | VIAF ID | 316561757 |
| P10832 | WorldCat Entities ID | E39PBJrm8B7hq83XWQHKb4jXBP |
| P734 | family name | Sexton | Q10816799 |
| Sexton | Q10816799 | ||
| Sexton | Q10816799 | ||
| P735 | given name | Patrick | Q18002623 |
| Patrick | Q18002623 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35994207 | "Ins and outs" of seven-transmembrane receptor signalling to ERK. |
| Q30439856 | 2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. |
| Q30433828 | 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists |
| Q50906602 | 4-Phenylpyridin-2-one Derivatives: A Novel Class of Positive Allosteric Modulator of the M1 Muscarinic Acetylcholine Receptor. |
| Q90472077 | 6-Phenylpyrimidin-4-ones as Positive Allosteric Modulators at the M1 mAChR: The Determinants of Allosteric Activity |
| Q27345100 | A Hydrogen-Bonded Polar Network in the Core of the Glucagon-Like Peptide-1 Receptor Is a Fulcrum for Biased Agonism: Lessons from Class B Crystal Structures |
| Q35643821 | A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation |
| Q47935295 | A kinetic view of GPCR allostery and biased agonism |
| Q28245604 | A new mechanism of allostery in a G protein-coupled receptor dimer |
| Q39947679 | A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. |
| Q38987775 | A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. |
| Q39167406 | A simple method to generate stable cell lines for the analysis of transient protein-protein interactions. |
| Q37281443 | Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor |
| Q24308061 | Activation and allosteric modulation of a muscarinic acetylcholine receptor |
| Q39856682 | Addition of a carboxy-terminal green fluorescent protein does not alter the binding and signaling properties of relaxin family Peptide receptor 3. |
| Q36880915 | Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. |
| Q56115675 | Allosteric Modulation of G Protein–Coupled Receptors |
| Q35454522 | Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. |
| Q34336467 | Allosteric modulation of G protein-coupled receptors. |
| Q37773544 | Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. |
| Q34076059 | Allosteric modulation of M1 muscarinic acetylcholine receptor internalization and subcellular trafficking |
| Q46120792 | Allosteric modulation of a chemogenetically modified G protein-coupled receptor. |
| Q51759155 | Allosteric modulation of endogenous metabolites as an avenue for drug discovery. |
| Q51755527 | Allosteric modulation of muscarinic acetylcholine receptors. |
| Q45974813 | Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. |
| Q38796999 | Allostery and Biased Agonism at Class B G Protein-Coupled Receptors |
| Q37932797 | Allostery in GPCRs: 'MWC' revisited. |
| Q41470108 | Amylin is an agonist of the renal porcine calcitonin receptor |
| Q36907408 | An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology |
| Q68454776 | Angiotensin II receptors in the kidney. Localization and physiological significance |
| Q44719359 | Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors |
| Q52565569 | Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptors. |
| Q36861067 | Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor |
| Q51742695 | Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor. |
| Q44329832 | Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor. |
| Q89812558 | Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs |
| Q34795759 | Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics |
| Q44080948 | Biologically active salmon calcitonin-like peptide is present in rat brain |
| Q55209075 | Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. |
| Q38062223 | Bridging the gap: bitopic ligands of G-protein-coupled receptors. |
| Q60601212 | Calcitonin receptor antibodies in the identification of osteoclasts |
| Q41359586 | Calcium inflow in cells transfected with cloned rat and porcine calcitonin receptors. |
| Q36472901 | Central nervous system binding sites for calcitonin and calcitonin gene-related peptide |
| Q41098257 | Characterization of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating hormone thyrotroph cell line |
| Q40413778 | Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. |
| Q38864019 | Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. |
| Q47249560 | Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms |
| Q50897824 | Coding GPCR-G protein specificity. |
| Q51075703 | Coexpressed Class B G Protein-Coupled Secretin and GLP-1 Receptors Self- and Cross-Associate: Impact on Pancreatic Islets. |
| Q55126622 | Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research. |
| Q28255872 | Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs |
| Q36153242 | Consequences of splice variation on Secretin family G protein-coupled receptor function |
| Q81391458 | Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors |
| Q50130085 | Correspondence: Reply to 'Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury'. |
| Q57838214 | Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands |
| Q59054344 | Cryo-EM structure of the active, G-protein complexed, human CGRP receptor |
| Q94551006 | Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide |
| Q92133857 | Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs |
| Q91472742 | Crystal structure of the M5 muscarinic acetylcholine receptor |
| Q43023574 | Delineating the mode of action of adenosine A1 receptor allosteric modulators |
| Q38926032 | Detection and quantification of allosteric modulation of endogenous m4 muscarinic acetylcholine receptor using impedance-based label-free technology in a neuronal cell line. |
| Q42829432 | Detection of novel functional selectivity at M3 muscarinic acetylcholine receptors using a Saccharomyces cerevisiae platform |
| Q60516357 | Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-r |
| Q34785475 | Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding |
| Q51746916 | Development of a photoactivatable allosteric ligand for the m1 muscarinic acetylcholine receptor. |
| Q51755093 | Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. |
| Q91158814 | Differential engagement of polar networks in the glucagon-like peptide 1 receptor by endogenous variants of the glucagon-like peptide 1 |
| Q51744814 | Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. |
| Q88424190 | Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold |
| Q33289718 | Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs |
| Q53689539 | Divergent effects of strontium and calcium-sensing receptor positive allosteric modulators (calcimimetics) on human osteoclast activity. |
| Q57804937 | Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H receptor antagonists |
| Q42921396 | Effects of conformational restriction of 2-amino-3-benzoylthiophenes on A(1) adenosine receptor modulation |
| Q41131918 | Electrophoretic mobility and glycosylation characteristics of heterogeneously expressed calcitonin receptors |
| Q27022831 | Endogenous allosteric modulators of G protein-coupled receptors |
| Q37635257 | Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders |
| Q39934952 | Evidence for a new subclass of calcitonin/ calcitonin gene-related peptide binding site in rat brain. |
| Q51451305 | Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. |
| Q49898093 | Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. |
| Q51794822 | Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. |
| Q48946039 | Function of the rat calcitonin receptors, C1a and C1b, expressed in Xenopus oocytes. |
| Q22242288 | Functional Selectivity and Classical Concepts of Quantitative Pharmacology |
| Q41883095 | Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor |
| Q47301249 | G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. |
| Q46421423 | G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor |
| Q28268136 | GPCR modulation by RAMPs |
| Q35830953 | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. |
| Q33615669 | Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R) |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q34454930 | Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. |
| Q91340888 | Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists |
| Q39738818 | H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). |
| Q80398194 | Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis |
| Q51253032 | High throughput, quantitative analysis of human osteoclast differentiation and activity. |
| Q41155947 | Homologous regulation of the rat C1a calcitonin receptor (CTR) in nonosteoclastic cells is independent of CTR messenger ribonucleic acid changes and cyclic adenosine 3',5'-monophosphate-dependent protein kinase activation |
| Q46542064 | Homology modeling of GPCRs. |
| Q28285761 | Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function |
| Q39314038 | Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. |
| Q45804689 | Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators |
| Q34672123 | Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. |
| Q47094111 | Improving virtual screening of G protein-coupled receptors via ligand-directed modeling. |
| Q72432118 | In vitro autoradiographic localization of amylin binding sites in rat brain |
| Q44984525 | In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain |
| Q71630934 | In vitro autoradiographic localization of the calcitonin receptor isoforms, C1a and C1b, in rat brain |
| Q46522310 | Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling |
| Q51807572 | Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. |
| Q34429173 | International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. |
| Q28201576 | International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors |
| Q35995202 | Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41. |
| Q39173097 | Isoform-Specific Biased Agonism of Histamine H3 Receptor Agonists |
| Q72019750 | Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction |
| Q28278129 | Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in Class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor |
| Q40659394 | Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists |
| Q51413360 | Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy. |
| Q43864464 | Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. |
| Q48271361 | Localization of binding sites for calcitonin gene-related peptide in rat brain by in vitro autoradiography |
| Q34547610 | M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss |
| Q36483064 | Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. |
| Q90929094 | Mechanisms of signalling and biased agonism in G protein-coupled receptors |
| Q34580443 | Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. |
| Q56286575 | Mini ReviewCalcitonin |
| Q37050373 | Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery |
| Q37371266 | Modulating receptor function through RAMPs: can they represent drug targets in themselves? |
| Q90784706 | Molecular Basis of Action of a Small-Molecule Positive Allosteric Modulator Agonist at the Type 1 Cholecystokinin Holoreceptor |
| Q36683781 | Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. |
| Q38755530 | Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators |
| Q51797732 | Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. |
| Q37175130 | Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor. |
| Q37608542 | Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor. |
| Q30498538 | Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties |
| Q34140989 | Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor |
| Q78801170 | Molecular pharmacology of class II G protein-coupled receptors. Introduction |
| Q28203305 | Molecular pharmacology of the calcitonin receptor |
| Q42362229 | Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions |
| Q28509700 | Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function |
| Q73330078 | Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product |
| Q35897933 | Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants |
| Q52684297 | Muscarinic M5 receptors modulate ethanol seeking in rats. |
| Q38218059 | Muscarinic acetylcholine receptors: novel opportunities for drug development |
| Q46483028 | New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). |
| Q28081112 | Novel Allosteric Modulators of G Protein-coupled Receptors |
| Q48160747 | Novel Irreversible Agonists Acting at the A1 Adenosine Receptor |
| Q28215813 | Novel receptor partners and function of receptor activity-modifying proteins |
| Q68687096 | O-GlcNAc Engineering of GPCR Peptide-Agonists Improves Their Stability and in Vivo Activity |
| Q43088304 | Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor |
| Q37547722 | Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. |
| Q60299786 | Overview of Receptor Allosterism |
| Q45251469 | Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes |
| Q39936717 | Pharmacology of 5HT(2C) receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing |
| Q52375459 | Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. |
| Q35761175 | Photoaffinity scanning in the mapping of the peptide receptor interface of class II G protein-coupled receptors. |
| Q35999406 | Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. |
| Q48354605 | Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior. |
| Q112573816 | Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia |
| Q39419158 | Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. |
| Q50692095 | Prediction of Loops in G Protein-Coupled Receptor Homology Models: Effect of Imprecise Surroundings and Constraints. |
| Q43064157 | Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae |
| Q42726130 | Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects |
| Q34373847 | Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor |
| Q88734577 | Probing the binding site of novel selective positive allosteric modulators at the M1 muscarinic acetylcholine receptor |
| Q39988617 | Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis |
| Q35124350 | Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias |
| Q48517809 | Purification of calcitonin-like peptides from rat brain and pituitary. |
| Q51740302 | Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. |
| Q37995492 | RAMPs as drug targets |
| Q52352887 | Recent advances in the determination of G protein-coupled receptor structures. |
| Q38077226 | Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. |
| Q37778513 | Receptor activity modifying proteins and their potential as drug targets |
| Q34189307 | Receptor activity modifying proteins. |
| Q45711499 | Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors |
| Q45034314 | Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators |
| Q42467460 | Regulation of serotonin 5-HT2C receptors by chronic ligand exposure. |
| Q28256590 | Responses of GPCR135 to human gene 3 (H3) relaxin in CHO-K1 cells determined by microphysiometry |
| Q102070233 | Restoring Agonist Function at a Chemogenetically Modified M1 Muscarinic Acetylcholine Receptor |
| Q46003429 | Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor. |
| Q39341570 | Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. |
| Q112754748 | Routine sub-2.5 Å cryo-EM structure determination of GPCRs |
| Q35763289 | Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. |
| Q35763258 | Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation |
| Q37674601 | Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist |
| Q39289042 | Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. |
| Q37642476 | Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. |
| Q44659696 | Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor |
| Q36347742 | Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor |
| Q37635253 | Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs. |
| Q50470980 | Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. |
| Q90470032 | Structural basis of Gs and Gi recognition by the human glucagon receptor |
| Q44763882 | Structural biology: meet the B family |
| Q33911197 | Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. |
| Q36336103 | Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening |
| Q59082343 | Structural insights into G-protein-coupled receptor allostery |
| Q98564759 | Structure and dynamics of the active Gs-coupled human secretin receptor |
| Q51123994 | Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. |
| Q59060936 | Structure of the adenosine-bound human adenosine A1 receptor–Gi complex |
| Q49914169 | Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor. |
| Q51797215 | Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. |
| Q112583046 | Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity |
| Q60516228 | Structure–function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors |
| Q51761046 | Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. |
| Q35598494 | Synthesis and pharmacological evaluation of M4 muscarinic receptor positive allosteric modulators derived from VU10004. |
| Q51748572 | Synthesis and pharmacological evaluation of analogues of benzyl quinolone carboxylic acid (BQCA) designed to bind irreversibly to an allosteric site of the M ₁ muscarinic acetylcholine receptor. |
| Q50952521 | Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. |
| Q44337901 | Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. |
| Q28276469 | The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism |
| Q38805850 | The complexity of signalling mediated by the glucagon-like peptide-1 receptor. |
| Q43080040 | The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. |
| Q46989972 | The effects of C-terminal truncation of receptor activity modifying proteins on the induction of amylin receptor phenotype from human CTb receptors |
| Q46717098 | The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions |
| Q72396393 | The ontogeny of [125I]rat-alpha-CGRP binding sites in the spinal cord of sheep: a prenatal and postnatal study |
| Q35764030 | The receptor activity modifying protein family of G protein coupled receptor accessory proteins |
| Q40160819 | The relaxin family peptide receptor 3 activates extracellular signal-regulated kinase 1/2 through a protein kinase C-dependent mechanism. |
| Q36627558 | The role of kinetic context in apparent biased agonism at GPCRs |
| Q51769693 | The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. |
| Q51767664 | The synthesis and biological evaluation of 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophenes as allosteric modulators of the A1 adenosine receptor. |
| Q50098149 | To Bind or Not to Bind: Unravelling GPCR Polypharmacology. |
| Q91321389 | Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors |
| Q36869965 | Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor |
| Q38375736 | Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias |
| Q53282873 | Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. |
| Q93149038 | Update to Our Reader, Reviewer, and Author Communities-April 2020 |
| Q93172202 | Update to Our Reader, Reviewer, and Author Communities-April 2020 |
| Q93182302 | Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism |
| Q36650346 | Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor |
| Q57157634 | Utility of an "allosteric site-impaired" M2 muscarinic acetylcholine receptor as a novel construct for validating mechanisms of action of synthetic and putative endogenous allosteric modulators |
| Q88352261 | Vascular and molecular pharmacology of the metabolically stable CGRP analogue, SAX |
| Q43294448 | β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues. |
Search more.